Achillion stock: buy or sell?
June 26th, 2019
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally.
Should I buy Achillion stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Only 1 of our buy setups matches with Achillion stock now:
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||Yes|
Is Achillion stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we found 1 rating published for ACHN stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
Achillion stock analysis
Achillion Pharmaceuticals ended today at $2.68 and declined a fateful -1.47%.
Shares of Achillion Pharmaceuticals closed today at $2.68 and declined a fateful -1.47%. Since price and SMA200d lines crossed down on Friday, ACHN fell $-0.20 per share (-6.94%). Since SMA100d and SMA200d crossed up on June 19th, ACHN price slid a -10.96%.
Achillion shares eased -3.94% this week, ending at $2.68. Late May ACHN plunged a spooky -7.75% in just one week.
Crossing through will mean looking for lower support lines and further price slices. In contrast, if ACHN finds a support at mark, it would be defining a double bottom pattern and a possible flat-base, something to be optimistic about. This week, Achillion stock crossed down the significant level of the 40-weeks moving average. Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Since SMA20w and SMA40w crossed up by mid June, ACHN price slid a -4.29%.
Achillion stock price history
Achillion stock went public on November 9th, 2006 with a price of $14.001. Since then, ACHN stock declined a -80.90%, with a yearly average of -6.70%.
1: Adjusted price after possible price splits or reverse-splits.
Achillion stock historical price chart
ACHN stock reached 52-week highs on October at $3.98, and all-time highs 2007-02-01 with a price of 20.
Achillion stock price target is $2.50Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ACHN stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we only found 1 price target for Achillion Pharmaceuticals stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareAchillion let down analysts on March when it posted an Earnings per Share (EPS) of $-0.12 when the market consensus was $-0.15.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2016, Achillion Pharmaceuticals annual revenues plunged a bloodcurdling -77.31% to $15.00 M USD from $66.12 marked in 2015. When comparing 2016 vs 2015, aligned with this, profit margin (that is, the net income divided by revenues) plummed a -403.77% to -411.37%.
|2015||$66 M||-||$-5.03 M-7.6%||-|
|2016||$15 M||-77.31%||$-61.71 M-411.4%||1,126.76%|
Quarterly financial resultsReported quarter income marked $-16.60 million with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Achillion Pharmaceuticals sales marked a neutral movement and remained steady a nan%. Looking back to recent quarterly results, Achillion posted 7 positive quarters in a row.
Achillion ownershipWhen you are planning to buy shares of a company, it's worth to check its ownership structure.
Achillion Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.15% of all shares.
In case of Achillion Pharmaceuticals stock, 78.62% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ACHN stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$371.8 M||$100.6 B||$73.7 B||$1.6 B||$84.7 B|
|Total shares||138.7 M||1,480.0 M||1,640.0 M||19.7 M||1,270.0 M|
|Float shares||124.7 M||1,480.0 M||1,630.0 M||15.0 M||1,270.0 M|
|- Institutional holdings (%)||78.6%||71.9%||75.0%||87.4%||82.6%|
|- Insider holdings (%)||0.1%||0.1%||0.1%||24.9%||0.7%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Wednesday, June 26th, 2019|
|Day range||$2.68 - $2.78|
|Average true range||$0.12|
|50d mov avg||$2.91|
|100d mov avg||$2.85|
|200d mov avg||$2.80|
Achillion performanceTo better understand Achillion Pharmaceuticals performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Achillion Pharmaceuticals against AbbVie, Bristol-Myers Squibb, Enanta Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, , Merck, Neogen, NanoViricides and Vertex Pharmaceuticals in the following table: